Oncobit is a MedTech spin-off from the University of Zurich, developing precision diagnostic and monitoring assays for personalized cancer care. Oncobit’s products aim at providing a detailed understanding of genomic cancer alterations throughout the patient’s history. Highly sensitive diagnostic and monitoring tools allow Oncobit to deliver the most appropriate treatment selections and to help physicians improve the treatment options they provide to their patients. Oncobit is addressing the rapidly expanding market of precision oncology and personalized disease monitoring using non-invasive technologies. The company’s current focus lies on melanoma, but Oncobit’s approach is data-centric, modular, and expandable to other cancer types in the near future.